Every material Form 8-K Oscar Health, Inc. has filed with the SEC since August 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Oscar Health reported third-quarter 2026 net income attributable to the company of $167.3 million, or $0.49 per diluted share, compared with a net loss of $137.5 million, or $(0.53) per diluted share, a year earlier. The company also raised its full-year 2026 earnings from operations outlook to $850 million to $950 million, up from $600 million to $800 million, which points to a stronger profit picture for shareholders.
Third-quarter total revenue was $5.1 billion, compared with $3.0 billion in the third quarter of 2025, driven by rate increases and higher membership.
Medical loss ratio was 84.0% for the quarter, compared with 88.5% a year earlier; earnings from operations were $178.0 million, compared with a loss of $129.3 million.
Third-quarter revenue included a $250 million benefit from updated risk adjustment estimates.
Full-year 2026 total revenue outlook was raised to $19.0 billion to $19.3 billion, from $18.7 billion to $19.0 billion.
Oscar Health said it will raise its full year 2026 guidance for earnings from operations to $600 million to $800 million, up $100 million from its prior expectation, and narrow its medical loss ratio outlook to 81.0% to 82.0%. It will reaffirm total revenue guidance of $18.7 billion to $19.0 billion and its SG&A expense ratio range of 15.6% to 16.1%, and will discuss strategy and long-term financial targets at its Investor Day on September 16, 2026.
Earnings from operations guidance raised to $600 million to $800 million, from $500 million to $700 million.
Medical loss ratio guidance improved to 81.0% to 82.0%, from a prior 81.5% to 82.5%.
Total revenue ($18.7 billion to $19.0 billion) and SG&A expense ratio (15.6% to 16.1%) guidance reaffirmed; Investor Day webcast held September 16, 2026.
Oscar Health reported second-quarter 2026 total revenue of $4.9 billion, up from $2.9 billion a year earlier, and net income attributable to the company of $361.8 million, or $1.10 per diluted share, compared with a loss of $228.4 million, or $(0.89) per share, in the second quarter of 2025. The company also raised its full-year 2026 earnings from operations guidance to $500 million to $700 million from $250 million to $450 million, which points to higher expected profitability for shareholders.
Q2 2026 medical loss ratio was 79.2%, compared with 91.1% in Q2 2025, which the company attributed partly to $164 million of favorable prior period reserve development.
Q2 2026 earnings from operations were $388.6 million, compared with a loss from operations of $230.5 million in Q2 2025.
Full-year 2026 guidance for medical loss ratio was lowered to 81.5% to 82.5% from 82.4% to 83.4%, and total revenue guidance of $18.7 billion to $19.0 billion was unchanged.
Effectuated membership was 2,963,002 as of June 30, 2026, compared with 2,027,148 a year earlier.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Oscar Health, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →